A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
Status:
Completed
Trial end date:
2014-07-29
Target enrollment:
Participant gender:
Summary
This is a 2-part (6 weeks duration for each part), randomized, double-blind,
placebo-controlled study in participants with rheumatoid arthritis. The hypothesis is that
etoricoxib (60 mg and 90 mg) administration will demonstrate superior efficacy compared to
placebo after 6 weeks of treatment, as measured by the greater mean improvement from baseline
in the Disease Activity Score C-Reactive Protein (DAS-28 CRP), and by the greater mean
improvement in Patient Global Assessment of Pain (PGAP) from baseline over 6 weeks of
treatment. Additionally, the added benefit of increasing the dose of etoricoxib from 60 mg to
90 mg will be assessed in the second part of the study.